Augmented Pulse Pressure Variation to Predict Fluid Responsiveness in Open Laparotomy

March 2, 2016 updated by: Jong Hwan Lee, Samsung Medical Center

Pulse Pressure Variation With Augmented Ventilation to Predict Fluid Responsiveness in the Patients Undergoing Open Laparotomy Surgery

Pulse pressure variation (PPV) is a well-known and widely used dynamic preload indicator based on heart-lung interaction to predict fluid responsiveness. Generally, patients are considered to be fluid-responsive when the PPV value larger than 11-13%. However, several previous researches demonstrated that there is a zone of uncertainty (grey zone) in PPV. To predict fluid-responsiveness accurately in the patients with PPV within grey zone (9-13%), the investigators would evaluate the augmented PPV using augmented ventilation.

Study Overview

Study Type

Observational

Enrollment (Actual)

38

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Adult patients undergoing elective open laparotomy surgery.

Description

Inclusion Criteria:

  • Adult patients undergoing elective open laparotomy surgery.

Exclusion Criteria:

  • Irregular heart beats,
  • cardiac arrhythmia,
  • moderate or severe valvular heart disease,
  • preoperative left ventriular ejection fraction less than 40%,
  • moderate t severe obstructive pulmonary disease,
  • preoperative need of inotropics infusion,
  • preoperative serum Cr > 1.3ml/dl,
  • moderate to severe renal or liver disease,
  • acute lung injury or acute lung problem,
  • coexisting open chest condition,
  • severe bradycardia,
  • patients with spontaneous breathing

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Augmented ventilation with fluid loading
This is an observational study and as a diagnostic intervention, subjects in the study would receive mechanical ventilation with augmented tidal volume of 12ml/kg for 2min. Augmented ventilation is performed when the patient's PPV is within grey zone (9-13%). The investigators perform this procedure to every patients and do not assigh this intervention to the subjects of the study. Then, 6ml/kg of ballanced crystalloid loading will be infused to every patient.
When the patient's PPV is within grey zone, patient's tidal volume is maintained with augmented tidal volume of 12 ml/kg (from normal ventilation of 8ml/kg) for 2min duration.
We record the stroke volume index (SVI) values before and after volume expansion with 6ml/kg of balanced crystalloid
Other Names:
  • Balanced crystalloid infusion

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Augmented PPV (Pulse Pressure Variation) to predict fluid responsiveness
Time Frame: within 2 min from augmented ventilation
Augmented ventilation (12ml/kg) will be performed when the participant's PPV is within grey zone (9-13%). PPV value will be collected automatically by Intelivue philips patient monitor. Percentage changes in stroke volume index by EV1000 according to fluid loading were used as principal indicators of fluid responsiveness. Patients were classified as responders or non-responders when increases in SVI were ≥ 10% or <10% after volume loading (crystalloid iv 6ml/kg). To test the abilities of augmented PPV to predict fluid responsiveness, areas under the receiver operating characteristics (ROC) curves of the responders [area under the curve (AUC) = 0.5: no better than chance, no prediction possible; AUC = 1.0: best possible prediction] will be calculated.
within 2 min from augmented ventilation

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Conventional baseline PPV to predict fluid responsiveness
Time Frame: when patients PPV in grey zone, before augmented ventilation
PPV value will be collected automatically by Intelivue philips patient monitor.
when patients PPV in grey zone, before augmented ventilation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2015

Primary Completion (Actual)

February 1, 2016

Study Completion (Actual)

February 1, 2016

Study Registration Dates

First Submitted

October 20, 2015

First Submitted That Met QC Criteria

January 9, 2016

First Posted (Estimate)

January 12, 2016

Study Record Updates

Last Update Posted (Estimate)

March 4, 2016

Last Update Submitted That Met QC Criteria

March 2, 2016

Last Verified

March 1, 2016

More Information

Terms related to this study

Other Study ID Numbers

  • SMC 2015-06-015

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Abdominal Neoplasms

Clinical Trials on Augmented ventilation

3
Subscribe